WISP1/CCN4: A Potential Target for Inhibiting Prostate Cancer Growth and Spread to Bone

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Ono, Mitsuaki ^a,d   Inkson, Colette A ^a,e   Sonn, Robert ^a   Kilts, Tina M ^a   de Castro, Luis F ^a   Maeda, Azusa ^a   Fisher, Larry W ^a   Robey, Pamela G ^a   Berendsen, Agnes D ^a   Li, Li ^a   McCartney Francis, Nancy ^a   Brown, Aaron C ^a   Crawford, Nigel P S ^b   Molinolo, Alfredo ^a   Jain, Alka ^c   Fedarko, Neal S ^c   Young, Marian F ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OKAYAMA UNIVERSITY   (Japan)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; WNT INDUCED SECRETED PROTEIN 1; WNT INDUCED SECRETED PROTEIN 1 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIBODIES; BONE NEOPLASMS; CCN INTERCELLULAR SIGNALING PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOHISTOCHEMISTRY; INJECTIONS; LUCIFERASES; MALE; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881509716     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071709     Document Type: Article

References (48)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, et al (2012) International variation in prostate cancer incidence and mortality rates. European urology 61: 1079-1092.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Barqawi AB, Krughoff KJ, Eid K, (2012) Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. Adv Urol 2012: 862639.
4. Gururajan M, Posadas EM, Chung LW, (2012) Future perspectives of prostate cancer therapy. Transl Androl Urol 1: 19-32.
5. Weilbaecher KN, Guise TA, McCauley LK, (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11: 411-425.
6. Roodman GD (2012) Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev.
7. Suva LJ, Washam C, Nicholas RW, Griffin RJ, (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7: 208-218.
8. Chen CC, Lau LF, (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41: 771-783.
9. Hashimoto Y, Shindo-Okada N, Tani M, Nagamachi Y, Takeuchi K, et al. (1998) Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses In vivo tumor growth and metastasis of K-1735 murine melanoma cells. J Exp Med 187: 289-296.
10. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, et al. (1998) WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95: 14717-14722.
11. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ, (2000) WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 14: 585-595.
12. Nagai Y, Watanabe M, Ishikawa S, Karashima R, Kurashige J, et al. (2011) Clinical significance of Wnt-induced secreted protein-1 (WISP-1/CCN4) in esophageal squamous cell carcinoma. Anticancer Res 31: 991-997.
13. Hou CH, Chiang YC, Fong YC, Tang CH, (2011) WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells. Biochem Pharmacol 81: 1286-1295.
14. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP, (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61: 8917-8923.
15. Bauer M, Su G, Casper C, He R, Rehrauer W, et al. (2010) Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 29: 1732-1740.
16. Pasmant E, Ortonne N, Rittie L, Laurendeau I, Levy P, et al. (2010) Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis. J Neuropathol Exp Neurol 69: 60-69.
17. Khor TO, Gul YA, Ithnin H, Seow HF, (2006) A comparative study of the expression of Wnt-1, WISP-1, survivin and cyclin-D1 in colorectal carcinoma. Int J Colorectal Dis 21: 291-300.
18. Margalit O, Eisenbach L, Amariglio N, Kaminski N, Harmelin A, et al. (2003) Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. Br J Cancer 89: 314-319.
19. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, et al. (2001) A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 20: 5525-5532.
20. Tang Q, Jiang X, Li H, Lin Z, Zhou X, et al. (2011) Expression and prognostic value of WISP-1 in patients with endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res 37: 606-612.
21. French DM, Kaul RJ, D'Souza AL, Crowley CW, Bao M, et al. (2004) WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol 165: 855-867.
22. Ono M, Inkson CA, Kilts TM, Young MF, (2011) WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity. J Bone Miner Res 26: 193-208.
23. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, et al. (2005) Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146: 1727-1736.
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92: 3439-3443.
25. Sun YX, Schneider A, Jung Y, Wang J, Dai J, et al. (2005) Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20: 318-329.
26. Inkson CA, Ono M, Bi Y, Kuznetsov SA, Fisher LW, et al. (2009) The potential functional interaction of biglycan and WISP-1 in controlling differentiation and proliferation of osteogenic cells. Cells Tissues Organs 189: 153-157.
27. Inkson CA, Ono M, Kuznetsov SA, Fisher LW, Robey PG, et al. (2008) TGF-beta1 and WISP-1/CCN-4 can regulate each other's activity to cooperatively control osteoblast function. J Cell Biochem 104: 1865-1878.
28. Joyce JA, Pollard JW, (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
29. Chirgwin JM, Guise TA, (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10: 159-178.
30. Langley RR, Fidler IJ, (2011) The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128: 2527-2535.
31. Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, et al. (2011) Cyr61 expression in Osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res.
32. Lv H, Fan E, Sun S, Ma X, Zhang X, et al. (2009) Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. J Cell Biochem 106: 738-744.
33. Terada N, Kulkarni P, Getzenberg RH, (2012) Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl 14: 405-408.
34. Terada N, Shiraishi T, Zeng Y, Mooney SM, Yeater DB, et al. (2012) Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. Prostate 72: 966-976.
35. Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, et al. (2009) The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 69: 775-784.
36. Tan TW, Yang WH, Lin YT, Hsu SF, Li TM, et al. (2009) Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. Carcinogenesis 30: 258-268.
37. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, et al. (2006) Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21: 1045-1059.
38. Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, et al. (2001) Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol 54: 275-280.
39. Kleer CG, Zhang Y, Merajver SD, (2007) CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs 185: 95-99.
40. Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, et al. (2006) Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 66: 5816-5827.
41. Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, et al. (2009) WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 119: 772-787.
42. Chung LW, Baseman A, Assikis V, Zhau HE, (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20.
43. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, et al. (2006) Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38: 154-166.
44. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, et al. (2007) BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171: 1047-1057.
45. Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, et al. (2011) Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med 208: 2641-2655.
46. Parisi MS, Gazzerro E, Rydziel S, Canalis E, (2006) Expression and regulation of CCN genes in murine osteoblasts. Bone 38: 671-677.
47. Kapinas K, Lowther KM, Kessler CB, Tilbury K, Lieberman JR, et al. (2012) Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol 31: 299-307.
48. Barry MJ, (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344: 1373-1377.